Tobin Schilke Revance Therapeutics, Inc. (RVNC) insider trading activity

Tobin Schilke is CFO of Revance Therapeutics, Inc.. Currently has a direct ownership of 0 shares of RVNC, which is worth approximately $0. The most recent transaction as insider was on Feb 06, 2025, when has been sold 124,438 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

100.0% 3M change

100.0% 12M change

Total Value Held $0

Tobin Schilke Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 06 2025	SELL Sale (or disposition) back to the issuer	-	124,438 Reduced 100.0%	0 Common Stock
Feb 06 2025	BUY Grant, award, or other acquisition	-	20,883 Added 50.0%	20,883 Common Stock
Feb 04 2025	SELL Disposition due to a tender of shares in a change of control transaction	$357,696 $3.65 p/Share	97,999 Reduced 48.62%	103,555 Common Stock
Feb 03 2025	BUY Grant, award, or other acquisition	-	6,888 Added 3.3%	201,554 Common Stock
Dec 31 2024	BUY Grant, award, or other acquisition	$2,180 $2.18 p/Share	1,000 Added 0.51%	194,666 Common Stock
Jun 30 2024	BUY Grant, award, or other acquisition	$2,180 $2.18 p/Share	1,000 Added 0.51%	193,666 Common Stock
Mar 18 2024	SELL Open market or private sale	$47,179 $5.04 p/Share	9,361 Reduced 4.63%	192,666 Common Stock
Mar 15 2024	SELL Payment of exercise price or tax liability	$20,256 $5.3 p/Share	3,822 Reduced 1.86%	202,027 Common Stock
Feb 29 2024	BUY Grant, award, or other acquisition	-	17,447 Added 7.81%	205,849 Common Stock
Jan 31 2024	BUY Grant, award, or other acquisition	-	96,667 Added 33.91%	188,402 Common Stock
Dec 31 2023	BUY Grant, award, or other acquisition	$3,241 $7.47 p/Share	434 Added 0.47%	91,735 Common Stock
Aug 11 2023	SELL Payment of exercise price or tax liability	$212,075 $18.91 p/Share	11,215 Reduced 10.94%	91,301 Common Stock
Aug 11 2023	BUY Grant, award, or other acquisition	-	22,620 Added 18.08%	102,516 Common Stock
Jul 03 2023	SELL Open market or private sale	$42,593 $25.04 p/Share	1,701 Reduced 2.08%	79,896 Common Stock
Jun 30 2023	BUY Grant, award, or other acquisition	$12,004 $15.61 p/Share	769 Added 0.93%	81,597 Common Stock
Jun 02 2023	SELL Open market or private sale	$15,500 $31.0 p/Share	500 Reduced 0.61%	80,828 Common Stock
Jun 01 2023	SELL Open market or private sale	$82,569 $30.57 p/Share	2,701 Reduced 3.21%	81,328 Common Stock
May 15 2023	SELL Open market or private sale	$739,404 $34.55 p/Share	21,401 Reduced 20.3%	84,029 Common Stock
May 01 2023	SELL Open market or private sale	$101,471 $31.7 p/Share	3,201 Reduced 4.83%	63,081 Common Stock
Apr 03 2023	SELL Open market or private sale	$102,912 $32.15 p/Share	3,201 Reduced 4.61%	66,282 Common Stock
Mar 15 2023	SELL Payment of exercise price or tax liability	$114,600 $30.65 p/Share	3,739 Reduced 5.11%	69,483 Common Stock
Mar 09 2023	SELL Open market or private sale	$584,952 $31.59 p/Share	18,517 Reduced 20.18%	73,222 Common Stock
Mar 01 2023	SELL Open market or private sale	$107,233 $33.5 p/Share	3,201 Reduced 6.09%	49,390 Common Stock
Feb 15 2023	SELL Payment of exercise price or tax liability	$69,242 $33.21 p/Share	2,085 Reduced 3.81%	52,591 Common Stock
Feb 01 2023	SELL Open market or private sale	$110,754 $34.6 p/Share	3,201 Reduced 5.53%	54,676 Common Stock

Tobin Schilke

CFO

Nashville, TN

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RVNC shares.

Notify only if

Value

Insider Trading

Get notified when an Revance Therapeutics, Inc. insider buys or sells RVNC shares.

Notify only if

Operation

Value

Type

News

Receive news related to Revance Therapeutics, Inc.

Track Activities on RVNC

Account